The present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI).
We performed a sub-analysis of a multicenter retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations.
Three hundred and twenty-nine patients were enrolled, 244 males and 85 females. Median age was 65.5 years. The prognostic impact of the Hb/RDW ratio on PFS and OS was observed in the whole population examined. Hb/RDW ratio had a correlation with neutrophil-to-lymphocyte ratio (NLR), a blood inflammatory parameter.
Hb/RDW ratio is a new inflammatory prognostic factor, easy to use in daily clinical practice.
This study examined patients with advanced kidney cancer treated with immunotherapy combinations, focusing on the Hb/RDW ratio, a simple measure from routine blood tests comparing hemoglobin levels to red blood cell size variation. The findings showed that patients with a lower Hb/RDW ratio had shorter survival. This suggests that the Hb/RDW ratio could be a useful tool for predicting patient outcomes. The ratio’s association with inflammation, which is known to influence cancer progression, may explain its significance. The hope is that the Hb/RDW ratio could help doctors make better treatment decisions for patients with advanced kidney cancer.
Immunotherapy. 2025 Jan 20 [Epub ahead of print]
Matilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, Sara Rodella, Nicola Simoni, Eleonora Lai, Marco Maruzzo, Umberto Basso, Davide Bimbatti, Roberto Iacovelli, Annunziato Anghelone, Ondřej Fiala, Sara Elena Rebuzzi, Giuseppe Fornarini, Cristian Lolli, Francesco Massari, Matteo Rosellini, Veronica Mollica, Cecilia Nasso, Alessandro Acunzo, Enrico Maria Silini, Federico Quaini, Massimo De Filippo, Matteo Brunelli, Giuseppe L Banna, Pasquale Rescigno, Alessio Signori, Sebastiano Buti
Department of Medicine and Surgery, University of Parma, Parma, Italy., Oncology Unit, Macerata Hospital, Macerata, Italy., Medical Oncology Unit, University of Brescia, Brescia, Italy., Radiotherapy Unit, University Hospital of Parma, Parma, Italy., Oncology Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy., Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy., Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic., Medical Oncology Unit, Ospedale San Paolo institution, Savona, Italy., Department of Oncology and Hematology, Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy., Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Medical Oncology, Ospedale Santa Corona, Pietra Ligure, Italy., Department of Medicine and Surgery, Section of Radiology, University of Parma, Parma, Italy., Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona, Italy., Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK., Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK., Section of biostatistics, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy.